BullFrog AI Holdings (BFRG) Non Operating Income (2022 - 2026)
BullFrog AI Holdings' (BFRG) quarterly Non Operating Income came in at $47531.0 in Q2 2026, up 126.94% on a YoY basis from $20944.0 in Q2 2025, and up 157.12% quarter-over-quarter from $18486.0 in Q4 2025.
Analysis
BullFrog AI Holdings (BFRG) Non Operating Income (2022 - 2026) Analysis & Trends
BullFrog AI Holdings (BFRG) has reported Non Operating Income for 5 consecutive years, with $47531.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Non Operating Income rose 126.94% year-over-year to $47531.0; the trailing twelve-month figure through Jun 2026 stood at $105032.0 (down 38.4% YoY), and the FY2025 full-year result was $96568.0, down 60.22% from the prior year.
- Non Operating Income rose to $47531.0 in Q2 2026 per BFRG's latest filing, from $18486.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $70317.0 in Q2 2024 and bottomed at -$134902.0 in Q1 2023.
- Historically, Non Operating Income has averaged $3047.3 across 5 years, with a median of $38819.0 in 2023.
- The widest YoY moves for Non Operating Income: up 160.21% in 2023, down 737.48% in 2023.
- Over 5 years, Non Operating Income stood at -$112475.0 in 2022, then soared by 134.51% to $38819.0 in 2023, then surged by 39.15% to $54018.0 in 2024, then slumped by 65.78% to $18486.0 in 2025, then surged by 157.12% to $47531.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $47531.0, $18486.0, and $18071.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | -73.00 Mn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 387.00 Mn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 234.30 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | - |
| 10 | BullFrog AI Holdings | 9.27 Mn | 2.35 Mn | 106,899.00 | 47,531.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 47,531.00 |
| Dec 31, 2025 | 18,486.00 |
| Sep 30, 2025 | 18,071.00 |
| Jun 30, 2025 | 20,944.00 |
| Mar 31, 2025 | 39,067.00 |
| Dec 31, 2024 | 54,018.00 |
| Sep 30, 2024 | 56,477.00 |
| Jun 30, 2024 | 70,317.00 |
| Mar 31, 2024 | 61,924.00 |
| Dec 31, 2023 | 38,819.00 |
| Sep 30, 2023 | 51,166.00 |
| Jun 30, 2023 | 56,572.00 |
| Mar 31, 2023 | -134,902.00 |
| Dec 31, 2022 | -112,475.00 |
| Sep 30, 2022 | -124,141.00 |
| Jun 30, 2022 | -93,962.00 |
| Mar 31, 2022 | -16,108.00 |